These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 18991639)

  • 21. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
    Li Y; Seto E
    Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of HDACs--effective drugs against cancer?
    Müller S; Krämer OH
    Curr Cancer Drug Targets; 2010 Mar; 10(2):210-28. PubMed ID: 20201785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic therapy of cancer with histone deacetylase inhibitors.
    Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
    J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemical and structural biology of protein lysine deacetylases.
    Yoshida M; Kudo N; Kosono S; Ito A
    Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(5):297-321. PubMed ID: 28496053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Histone deacetylase inhibitors and cancer: from cell biology to the clinic.
    Hess-Stumpp H
    Eur J Cell Biol; 2005 Mar; 84(2-3):109-21. PubMed ID: 15819394
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond.
    Konstantinopoulos PA; Karamouzis MV; Papavassiliou AG
    Expert Opin Investig Drugs; 2007 May; 16(5):569-71. PubMed ID: 17461732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Histone deacetylases and cancer: causes and therapies.
    Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
    Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
    Singh AK; Bishayee A; Pandey AK
    Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors: molecular mechanisms of action.
    Xu WS; Parmigiani RB; Marks PA
    Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natural products as zinc-dependent histone deacetylase inhibitors.
    Tan S; Liu ZP
    ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in histone deacetylase targeted cancer therapy.
    Hoshino I; Matsubara H
    Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone deacetylase inhibitors: gathering pace.
    Carey N; La Thangue NB
    Curr Opin Pharmacol; 2006 Aug; 6(4):369-75. PubMed ID: 16781195
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HDAC inhibitors: a potential new category of anti-tumor agents.
    Pan LN; Lu J; Huang B
    Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human Diseases.
    Gatla HR; Muniraj N; Thevkar P; Yavvari S; Sukhavasi S; Makena MR
    Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30841513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation.
    Wagh NK; Deokar HS; Juvale DC; Kadam SS; Kulkarni VM
    Indian J Biochem Biophys; 2006 Dec; 43(6):360-71. PubMed ID: 17285800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
    Johnstone RW
    Nat Rev Drug Discov; 2002 Apr; 1(4):287-99. PubMed ID: 12120280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention.
    Yang XJ; Seto E
    Oncogene; 2007 Aug; 26(37):5310-8. PubMed ID: 17694074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
    Noureen N; Rashid H; Kalsoom S
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylases: target enzymes for cancer therapy.
    Mottet D; Castronovo V
    Clin Exp Metastasis; 2008; 25(2):183-9. PubMed ID: 18058245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.